首页> 外文OA文献 >Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients
【2h】

Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients

机译:潜在的尿miRNa生物标志物准确检测良性前列腺增生患者的前列腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MicroRNAs (miRNAs) are a class of short (similar to 22nt), single stranded RNA molecules that function as post-transcriptional regulators of gene expression. MiRNAs can regulate a variety of important biological pathways, including: cellular proliferation, differentiation and apoptosis. Profiling of miRNA expression patterns was shown to be more useful than the equivalent mRNA profiles for characterizing poorly differentiated tumours. As such, miRNA expression "signatures" are expected to offer serious potential for diagnosing and prognosing cancers of any provenance. The aim of this study was to investigate the potential of using deregulation of urinary miRNAs in order to detect Prostate Cancer (PCa) among Benign Prostatic Hyperplasia (BPH). To identify the miRNA signatures specific for PCa, miRNA expression profiling of 8 PCa patients, 12 BPH patients and 10 healthy males was carried out using whole genome expression profiling. Differential expression of two individual miRNAs between healthy males and BPH patients was detected and found to possibly target genes related to PCa development and progression. The sensitivity and specificity of miR-1825 for detecting PCa among BPH individuals was found to be 60% and 69%, respectively. Whereas, the sensitivity and specificity of miR-484 were 80% and 19%, respectively. Additionally, the sensitivity and specificity for miR-1825/484 in tandem were 45% and 75%, respectively. The proposed PCa miRNA signatures may therefore be of great value for the accurate diagnosis of PCa and BPH. This exploratory study has identified several possible targets that merit further investigation towards the development and validation of diagnostically useful, non-invasive, urine-based tests that might not only help diagnose PCa but also possibly help differentiate it from BPH.
机译:MicroRNA(miRNA)是一类短的(类似于22nt)单链RNA分子,可作为基因表达的转录后调节子。 MiRNA可以调节多种重要的生物学途径,包括:细胞增殖,分化和凋亡。研究表明,miRNA表达模式的分析比等价的mRNA谱对表征低分化肿瘤更有用。这样,预期miRNA表达“特征”将为诊断和预示任何来源的癌症提供严重的潜力。这项研究的目的是研究使用尿液miRNA失调来检测前列腺增生症(BPH)中的前列腺癌(PCa)的潜力。为了鉴定特异于PCa的miRNA特征,使用全基因组表达谱对8位PCa患者,12位BPH患者和10位健康男性进行miRNA表达谱分析。检测到健康男性和BPH患者之间两个单独的miRNA的差异表达,发现它们可能靶向与PCa发育和进程有关的基因。发现miR-1825检测BPH个体中PCa的敏感性和特异性分别为60%和69%。而miR-484的敏感性和特异性分别为80%和19%。另外,miR-1825 / 484的串联敏感性和特异性分别为45%和75%。因此,提出的PCa miRNA签名对于PCa和BPH的准确诊断可能具有重要价值。这项探索性研究确定了几个可能的目标,值得进一步研究,以开发和验证可用于诊断的,非侵入性的,基于尿液的测试,这些测试不仅可以帮助诊断PCa,而且还可以将其与BPH区分。

著录项

  • 作者

    Haj-Ahmad Yousef;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号